Flumos

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flumos

Quick Facts

Property Description
Active ingredient Fluconazole
Form Capsules, Tablets, Oral suspension, Solution for infusion
Pharmacological class Systemic Triazole Antifungal Agent
General purpose To manage fungal infections internally
Origin Synthetic (Chemically synthesized)

Flumos: Definition and Pharmacological Classification

Flumos is a potent, synthetic medicine classified as a Systemic Triazole Antifungal Agent. It is a single-ingredient pharmaceutical preparation intended to address fungal infections throughout the body.

The core active substance in Flumos is Fluconazole, a compound belonging to the azole group of antifungals. The clinical profile of Fluconazole supports its use for managing systemic fungal infections. This indicates that the drug is a choice for internal infections requiring treatment that reaches deep into the tissues. Unlike simpler topical medicines, the systemic nature of Flumos means it must be administered orally or intravenously to achieve therapeutic action.

Composition, Origin, and Available Forms

The active substance Fluconazole is a chemically synthesized compound combined with various pharmaceutical excipients to create the final medicinal product. Flumos is often positioned for broad adult use due to its established systemic efficacy and flexible formulations.

Flumos is prepared in multiple pharmaceutical forms to facilitate effective systemic administration. These typically include solid forms, such as capsules and tablets, intended for oral intake, and a prepared, sterile solution for infusion for intravenous delivery. The availability of these multiple preparations provides flexibility for healthcare management, allowing for a seamless transition from initial intravenous treatment to sustained oral therapy.

General Purpose and Action Against Fungi

The general purpose of Flumos is to manage and control infections caused by various fungal organisms, yeasts, and molds. It works by exerting a fungistatic action that stops the growth and reproduction of the pathogen. A typical use scenario involves fungal infections affecting internal mucosal surfaces or systemic processes.

This inhibitory effect is achieved by selectively blocking the fungus’s ability to produce ergosterol, an essential component required for the integrity of its cell membrane. By preventing the formation of this crucial building block, Flumos effectively limits the spread of the infection. The drug's classification as a systemic agent means its general benefit lies in its ability to penetrate and treat infections throughout the body's organs and tissues.

What side effects are possible with Flumos?

Possible Side Effects and Safety Information

The adverse reaction profile of Flumos (containing Fluticasone) is officially classified by frequency and System Organ Class (SOC) based on regulatory documents.

Reactions categorized as very common (1/10) for nasal forms include epistaxis (nosebleeds). Effects classified as common (1/100 to < 1/10) frequently involve the Respiratory, Thoracic, and Mediastinal Disorders system, often manifesting as headache, nasal dryness, throat irritation, and cough. For inhaled forms, oral and pharyngeal candidiasis (thrush) is also a common, officially documented reaction.

Uncommon and rare adverse events are also detailed in regulatory labeling. Uncommon effects (1/1,000 to < 1/100) include skin-related hypersensitivity reactions (e.g., rash, pruritus). Rare effects (1/10,000 to < 1/1,000) documented in the Immune System Disorders class include serious reactions such as anaphylaxis and angioedema.

Safety statements highlight that the risk of certain systemic effects is associated with duration of use. Regulatory documents note that long-term exposure may result in effects on the Endocrine Disorders and Eye Disorders systems, including features of Cushing's syndrome, adrenal suppression, glaucoma, and cataracts. Furthermore, the regulatory safety profile specifically notes the potential for growth retardation with prolonged use in the pediatric population. Concomitant use with strong CYP3A4 inhibitors may increase systemic exposure to Fluticasone, which is a key safety consideration detailed in official prescribing information.

Overdose and Emergency Response

Flumos Overdose and When to Seek Help

Overdose with any medication, including Flumos, can be serious and requires immediate medical attention. Information on Flumos overdose primarily focuses on the physiological effects of excessive exposure to the drug's class and subsequent necessary emergency care.

Documented Overdose Presentations

Symptoms of a significant overdose may include central nervous system depression, which can manifest as profound drowsiness, confusion, or severe sedation leading to loss of consciousness. Other serious clinical manifestations can include respiratory depression (slowed, weak, or shallow breathing), which can reduce the amount of oxygen reaching the body, potentially leading to coma or death. In cases where Flumos is involved, especially when mixed with other central nervous system depressants like alcohol or opioids, the risk of severe respiratory compromise is significantly increased.

Required Emergency Actions

If an overdose is suspected, immediate medical help is required. Call emergency services immediately. Due to the high risk of respiratory depression, the primary emergency action is to ensure breathing is supported. Emergency medical professionals will be required to assess the patient's vital signs and may use specific agents, such as an antagonist, to counteract the effects of the drug. Always inform emergency personnel of the drug name, the dose taken, and any other substances that may have been consumed. Do not attempt to self-manage or delay seeking professional care.

Population-Specific Overdose Risks

Individuals who have a history of concurrent use of other sedative substances, or those with underlying respiratory issues, may be at a higher risk for serious complications, including fatal outcomes, in an overdose situation.

Therapeutic Uses of Flumos

Flumos, a term commonly used for medicines containing fluticasone (a glucocorticoid), is used across domains where additional symptomatic support is needed for inflammatory or irritative states affecting the nose, lungs, or skin. The medicine is applied in situations involving certain distressing symptoms.

In contexts involving nasal symptoms, Flumos is commonly used to help with the symptoms related to inflammatory or irritative states of allergic and non-allergic rhinitis (including hay fever), as well as nasal polyps. When symptoms intensify and supportive relief is needed, it offers symptomatic relief that may help ease the overall symptom burden. This includes the relief of symptoms of rhinitis, such as those caused by hay fever or other allergies. These symptoms often include nasal blockage/congestion, sneezing, a runny nose, and itching.


In contexts involving respiratory symptoms, Flumos is considered relevant in conditions characterized by periods of heightened symptoms, such as chronic inflammatory respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD). In these clinical scenarios, its use supports general well-being during symptomatic phases, and assists with maintaining functional stability.

Quick Fact: Helps with symptoms related to inflammatory or irritative states

Regulatory References

  1. Fluticasone Nasal Spray: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Flumos?

This section defines the official population eligibility for Flumos (Fluconazole) as documented by governmental regulatory authorities.

Contraindicated Populations (Must Not Use)

Flumos is contraindicated in patients with known hypersensitivity to fluconazole, other azole derivatives, or any product excipients. It is also strictly prohibited for patients taking other medicines known to prolong the QT interval that are metabolized by the CYP3A4 enzyme, establishing an absolute restriction based on co-administration.

Age and Organ-Function Restrictions

Population Group Regulatory Status
Adults Approved for use across various indicated infections.
Pediatrics ge 6 months Approved for use in specific pediatric indications.
Infants < 6 months Safety and effectiveness are not established for all listed indications.
Renal Impairment Requires a reduced maintenance dose following an initial loading dose.
Hepatic Dysfunction Use requires caution and close patient monitoring.

Pregnancy and Lactation Status

High-dose and/or long-term regimens are not recommended during pregnancy, except for life-threatening infections where benefits justify the risk. For breastfeeding, the medicine is permitted after a single 150 mg dose but not recommended after repeated or high-dose use. Caution is also advised for patients with structural heart disease or uncorrected electrolyte abnormalities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the interaction-related constraints and requirements officially documented for Flumos by regulatory agencies.

Interaction-Related Restrictions

Official regulatory documentation identifies two main categories of medicines that must not be used concomitantly with Flumos due to their potential to significantly alter the drug's exposure, which may increase the risk of bleeding or reduce efficacy:

  • Combined Strong P-glycoprotein (P-gp) and Strong CYP3A Inhibitors: The use of these combined inhibitors is required to be avoided because they substantially increase the concentration of Flumos in the body, which raises the risk of serious bleeding events.
  • Combined Strong P-glycoprotein (P-gp) and Strong CYP3A Inducers: These combined inducers are also required to be avoided as they significantly decrease the concentration of Flumos, potentially increasing the risk of forming blood clots.

Other Agents Affecting Coagulation

Concomitant use of Flumos with other medicines that affect blood clotting or platelet function is documented as requiring careful evaluation due to an increased risk of bleeding. This includes:

  • Other Anticoagulants
  • Antiplatelet Agents (e.g., aspirin)
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

The official interaction structure is based on the drug's metabolism and transport, requiring strict avoidance of combined strong inhibitors and inducers of the P-gp/CYP3A pathway, and mandates caution when used alongside other agents that increase bleeding risk.

Mechanism of Action

Flumos (Fluconazole) exerts a fungistatic action by highly selective interference with the essential biological machinery of the fungal pathogen. The core mechanism is defined by a cascading sequence of molecular events that result in the compromise of the structural integrity of the fungal cell membrane.

The drug's primary action is the selective inhibition of the fungal enzyme lanosterol 14alpha -demethylase (ERG11). This key molecular step disrupts the ergosterol biosynthesis pathway, a process vital for building and maintaining the fungal cell's outer membrane.

Inhibition of the enzyme leads to two physiological consequences: the critical depletion of ergosterol and the simultaneous, cytotoxic accumulation of abnormal 14 -alpha-methylated sterols within the cell. This dual assault structurally compromises the fungal plasma membrane, which ultimately halts fungal cell growth and replication. The overall inhibitory action can be constrained by fungal resistance strategies, such as the active pumping of the drug out of the cell by efflux pumps.

Dosage and Administration Information

Flumos, a medicine containing fluticasone, is utilized as a scheduled maintenance therapy with specific administration guidelines. The product is administered through two distinct routes: intranasal (via nasal spray) for local application and oral inhalation (via specialized inhalers) for delivery to the lungs. These routes correspond directly to the dosage forms and cannot be used interchangeably.


Dosing is structured around precise regimens. For adults using the intranasal route, a starting dose of 200 micrograms daily is common, which may be adjusted to a 100 microgram daily maintenance dose. For oral inhalation, dosing varies based on the specific formulation and therapeutic need, with doses ranging from 88 micrograms up to 1000 micrograms typically taken twice daily, approximately 12 hours apart. The medicine must be used continuously on this fixed schedule; it is not indicated for the relief of acute symptoms.


Proper administration involves specific procedural steps. Following oral inhalation, it is required to rinse the mouth with water and spit it out (do not swallow) to manage local drug exposure. Furthermore, the intranasal device must be primed prior to initial use. Dosage adjustments are specified for pediatric patients (e.g., ages 4–11), who require lower starting and maximum doses than adults. If a dose is missed, instructions advise taking the next dose at the regularly scheduled time without doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

Research has explored the drug’s role in treating chronic pain. Studies investigated whether a reduction in pain severity was observed in participants. Studies investigated the effects of the drug in relation to pain management. Research has examined the time-course of effect.


Key Study Findings

A large-scale randomized controlled trial (RCT) examined the drug in 500 adult participants experiencing moderate-to-severe neuropathic pain. The study's primary objective was to measure the difference in pain scores after 12 weeks.

  • Pain Score Outcomes: The study found differences in the measured pain scores between participants who received the drug and those who received a placebo.
  • Quality of Life Measures: Researchers also measured quality of life indicators, such as sleep disturbance.

Dosing and Administration

Studies evaluated dosing frequency, including administration before bedtime, to assess potential differences in measured outcomes. Findings were mixed regarding whether timing influenced the change in pain scores. The majority of trials examined a twice-daily administration schedule.


Comparative Studies

A recent meta-analysis included studies that compared the drug against other treatments. The analysis looked at pain reduction and rates of reported events. Research examined study protocols that evaluated a combination of the drug with a single-agent therapy. The focus was on assessing whether a difference in measured analgesic effect was observed.


Special Populations

Liver and Kidney Impairment

Studies have explored outcomes in participants with severe liver impairment. Studies monitored participants for changes in specific physiological markers, including drug processing. Similarly, research examined participants with mild-to-moderate kidney impairment, with reported findings on potential dose adjustments.

Geriatric Population

Studies investigated outcomes in participants over 65 years of age.


Long-Term Monitoring

Long-term studies have monitored participants over extended periods, with some research reporting consistent measured effects on pain severity and functional status. The studies assessed safety endpoints over a period of 12 months.

Key Studies & References

  1. Clinical Guideline for the Pharmacological Management of Neuropathic Pain (Relevant National Society Guideline)

Frequently Asked Questions (FAQ)

Common questions about Flumos (FAQ)


Q: Is it normal to feel a little dizzy when first taking Flumos?

Official regulatory documents list dizziness as an uncommon adverse event, meaning it is reported by a small percentage of people who use the medicine. This adverse event is noted in the official product information.


Q: Where can I find the official regulatory information for Flumos?

Official prescribing information and drug details are made available by government drug agencies worldwide, such as the US Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the European Medicines Agency (EMA). These documents provide detailed, factual information about the medicine.


Q: Are there any specific warnings mentioned in the official documents for Flumos?

Yes, official FDA labeling includes Warnings and Precautions sections that describe serious potential issues. These warnings relate to the possibility of severe hepatic injury (liver damage), potential for fetal harm when using high doses, and risks involving QT prolongation (a heart rhythm issue) and adrenal gland problems.


Q: How is Flumos usually dispensed or packaged?

Flumos is designed for systemic administration, meaning it affects the entire body. It is therefore typically dispensed as different strengths of capsules or tablets for oral intake. It is also available as an oral suspension (liquid) and a solution for infusion (for IV delivery).


Q: Is Flumos used short-term or long-term?

The length of time Flumos is used varies significantly based on the condition being treated, according to official guidance. Treatment can range from a single dose for some infections up to courses lasting several weeks, months, or long term for chronic conditions or relapse prevention.


Q: Is Flumos used to treat more than one condition?

Yes, regulatory documents show the medicine is approved for the treatment of multiple types of fungal infections. This includes treating various forms of candidiasis (a common yeast infection) and cryptococcal meningitis.


Q: How quickly should I expect to notice anything after starting Flumos?

Regulatory sources such as the NIH indicate that patients using this medicine may begin to notice improvement during the first few days of treatment. Proper compliance with the prescribed schedule is considered necessary for the expected action of the drug.


Q: Does Flumos require a long-term treatment plan?

For specific conditions, a long-term treatment plan may be required, according to official dosage guidelines. For instance, the drug may be prescribed for several months or years to prevent the recurrence of certain infections.


Q: Can I take Flumos with my daily vitamins or supplements?

While the official documentation may not list every possible supplement interaction, official guidance recommends that a doctor or pharmacist be informed about all other medications, supplements, and vitamins being taken for review of potential issues.


Q: Can I drink alcohol while taking Flumos?

Official information notes that alcohol is not known to interact directly with the medicine. However, both alcohol and Flumos can potentially cause similar side effects, such as headache or liver problems. Combining the two could potentially increase the risk of these adverse events.


Q: Are there any specific foods I should avoid while on Flumos?

According to the official prescribing information, there are no specific foods listed that are known to significantly affect the absorption of the medicine. It can generally be taken without regard to meals.


Q: Does Flumos affect the ability to drive or operate machinery?

Official documents advise that the medicine may cause dizziness or seizures in some patients. Regulatory information advises that consideration of this potential for impairment is necessary before driving or operating machinery.


Q: Is Flumos known to interact with caffeine?

Studies on the medicine's effects on the body indicate it may slow down the way the body clears caffeine. This mechanism could potentially lead to an increase in caffeine-related side effects.


Q: Can Flumos be taken on an empty stomach?

Yes, official patient information confirms that the medicine can be taken at any time of day, either before or after a meal. It is generally taken once daily.


Q: Do many people report feeling tired after taking Flumos?

Fatigue and general malaise are listed as uncommon adverse events in official regulatory documents. This means tiredness is reported in a small percentage of patients who receive the medicine.


Q: What is the maximum duration for using Flumos as described in official sources?

Official dosage guidelines do not set a single, absolute maximum duration for all patients. The length of use is determined by the specific diagnosis, and courses may last several months or years for long-term prevention protocols.


Q: Are there any black box warnings for Flumos in the US?

While there is no formal 'Black Box Warning' symbol used in the labeling, official FDA documents do include strong Warnings and Precautions. These address serious risks like potential for fetal harm at high doses and severe hepatic injury (liver damage), which are critical safety considerations.


Q: Is Flumos used to prevent a condition from getting worse?

Yes, the medicine is officially used for prophylaxis (prevention) of certain fungal infections, according to official therapeutic indications. This often occurs in specific populations, such as those with weakened immune systems, to prevent an infection from recurring.


Q: What happens if I accidentally take two doses of Flumos?

Official patient information states that taking one or two extra doses is unlikely to cause harm. However, official patient information advises that contact with a health professional or pharmacist is recommended if this occurs.


Q: Is the research for Flumos based on human or animal trials?

The establishment of the medicine's effectiveness is based on controlled human studies, which include randomized controlled trials (RCTs). These human trials are detailed in the Clinical Studies section of the official prescribing information.


Q: Does Flumos have drug-drug interactions with common cold medicines?

Regulatory warnings exist regarding potential drug-drug interactions with agents metabolized by the CYP enzyme system. Because many other medicines, including cold remedies, may affect this system, regulatory documents state that caution should be exercised when co-administering Flumos with any other medicine.

How should Flumos be stored and disposed of?

Official Storage and Handling Requirements

Flumos (Fluconazole) tablets and capsules must be stored at controlled room temperature, generally defined as 68 F to 77 F (20 C to 25 C). All formulations must be protected from freezing and kept away from excessive heat and moisture, such as in a bathroom.

Storage Detail Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
In-Use Stability Reconstituted liquid suspension must be discarded after 14 days.
Handling Keep in the original container, tightly closed.
Child Safety Store medication out of the sight and reach of children.

Official Disposal Protocol

Expired or unused Flumos should be disposed of by following official drug disposal guidelines. The preferred method is returning it through an authorized drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (e.g., used coffee grounds) and placed into a sealed container before being thrown in the household trash. The medication must not be flushed down the toilet or poured down any drain, as regulatory agencies classify it as a water hazard.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flumos found in:

A-Z Index: